Biotechs Survive 2018 Bottom And Catch A Rally

Biotechs Survive 2018 Bottom But Enthusiasm Is Sketchy

Mid-Caps Should Move with M&A and News-Big Movers Today

Celgene Beats on Earnings and Strong Revlimid and Pomalyst Sales

The overall market rallied today with good strength in Nasdaq up 1.71 % and the QQQ up even better up 1.9% helped by AAPL up 3.97% on a huge buy program this week by Berkshire-Hathaway (BRK-A). Biotech stocks nudged up but short of major indices with the IBB up 1.06% at a quadruple bottom hit at first last August. The XBI tracked the QQQ up 1.7% just above the 200-day moving average (SMA) at $87.37. As we mentioned many times the XBI usually outperforms the IBB on rally days and longer term. The FBT is the best performing ETF in 2018 was up 1.29 % today. We expected a bigger rally today but has been a laggard with the XLV up only 0.7% today and at the $80 level below the 200 day SMA. The biotech sector was quite volatile in Q1 with highs hit in early February and mid-March followed by severe sell-offs.

Large caps are mixed now that most financial reports are in. Slightly in the green today were ALXN, AMGN, BIIB, CELG, GILD, and MRK. Celgene (CELG) Celgene and got some buying interest with the stock near its 12 month low. Celgene beat on revenues and profits but issues remain such as the recent regulatory delay on Ozanimod developed for relapsing multiple sclerosis (MS) which will be re-submitted  to the FDA in early 2019. Net Product sales were  $3,531 M for Q1 a 20% increase for the same period in 2017. Diluted EPS for Q1 was $1.10 compared to $1.15 in 2017. Celgene recently made two acquisitions for over $10M. The stock was up 1.74% today to $86.89.

We are developing a “tracking list” for what we believe is a “sweet spot” of the biopharmaceutical market, stocks that are more likely to move on M&A, and clinical milestones. A good example was the acquisition of Avexis (AVXS) by Novartis AG (NVS). We will update this list as we monitor news and stock performance. Our initial screening are mid-caps in the $2B-15B market cap range. For example, some big mid-cap movers up today are: ACAD, ALNY, BLUE, CRSP, LGND, NBIX, SRPT, and TSRO.

Print Friendly, PDF & Email
No tags for this post.

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *